INKT
MiNK Therapeutics Inc

1,792
Mkt Cap
$44.17M
Volume
28,289.00
52W High
$76.00
52W Low
$6.34
PE Ratio
-3.10
INKT Fundamentals
Price
$9.41
Prev Close
$9.74
Open
$9.50
50D MA
$11.28
Beta
0.65
Avg. Volume
6,618.68
EPS (Annual)
-$2.86
P/B
-3.20
Rev/Employee
$0.00
$26.64
Loading...
Loading...
News
all
press releases
MiNK Therapeutics (NASDAQ:INKT) Director Barbara Ryan Sells 1,300 Shares
MiNK Therapeutics, Inc. (NASDAQ:INKT - Get Free Report) Director Barbara Ryan sold 1,300 shares of MiNK Therapeutics stock in a transaction that occurred on Tuesday, March 10th. The shares were sold...
MarketBeat·11d ago
News Placeholder
More News
News Placeholder
Why Is MiNK Therapeutics Stock Trading Lower On Wednesday?
MiNK Therapeutics stock drops after a 30% rally as investors react to profit taking and a $1.1 million pediatric cancer therapy deal.read more...
Benzinga·11d ago
News Placeholder
Strategic Partnerships and Platform Plays Power New Momentum Across Tech and Healthcare
Markets open the session with strategic partnerships, infrastructure consolidation, and breakthrough technologies dominating the corporate news cycle; several companies are positioning themselves at the intersection of innovation and scalable commercialization. $INKT, $VTAK, $KBLB, $APP, $BEAT, $SGN, $STGW
24-7 Market News·12d ago
News Placeholder
MiNK Therapeutics Pediatric Cancer Breakthrough Sparks Stock Rally
MiNK Therapeutics' stock rises premarket after announcing a pediatric cancer cell therapy collaboration with C-Further and $1.1 million funding.read more...
Benzinga·12d ago
News Placeholder
Why Did INKT Stock Jump 30% Today?
MiNK Therapeutics tied up with an oncology consortium to develop a cell therapy targeting pediatric cancers.
Stocktwits·13d ago
News Placeholder
MiNK Therapeutics, Inc. (NASDAQ:INKT) Receives Consensus Rating of "Hold" from Brokerages
Shares of MiNK Therapeutics, Inc. (NASDAQ:INKT - Get Free Report) have received an average recommendation of "Hold" from the five ratings firms that are presently covering the stock, MarketBeat.com...
MarketBeat·1mo ago
News Placeholder
MiNK Therapeutics, Inc. (NASDAQ:INKT) Receives Consensus Recommendation of "Hold" from Analysts
Shares of MiNK Therapeutics, Inc. (NASDAQ:INKT - Get Free Report) have been given an average rating of "Hold" by the five research firms that are currently covering the company, MarketBeat Ratings...
MarketBeat·2mo ago
News Placeholder
Wall Street Zen Upgrades MiNK Therapeutics (NASDAQ:INKT) to "Hold"
Wall Street Zen raised shares of MiNK Therapeutics from a "sell" rating to a "hold" rating in a research report on Monday...
MarketBeat·2mo ago
News Placeholder
MiNK Therapeutics (NASDAQ:INKT) Downgraded by Wall Street Zen to "Sell"
Wall Street Zen cut shares of MiNK Therapeutics from a "hold" rating to a "sell" rating in a report on Sunday...
MarketBeat·2mo ago
News Placeholder
MiNK Therapeutics (NASDAQ:INKT) Stock Rating Upgraded by Wall Street Zen
Wall Street Zen raised MiNK Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday...
MarketBeat·3mo ago
<
1
2
...
>

Latest INKT News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.